Our rapidly growing pharmaceutical pipeline

Our lead program is a novel drug candidate for NASH and Cardiovascular Disease

All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. This is an unprecedented clinical opportunity. This genetically validated asset is currently in preclinical development. Contact us to find out more.

G3T's diagnostic pipeline

knowPLAQUE: a novel, simple blood test to diagnose the presence or absence of coronary artery disease

G3T has discovered, validated and patented a revelationary blood test that can detect the presence or absence of harmful plaques in the heart that lead to heart attacks and sudden cardiac death.

Patent has been granted on this blood test both in the United States and in Europe.

NO RADIATION. NO HASSLE. knowPLAQUE.